These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6961973)

  • 1. Role of the host in the variable chemotherapeutic response of advanced Ridgway osteogenic sarcoma.
    Nelson JA; Hokanson JA; Jenkins VK
    Cancer Chemother Pharmacol; 1982; 9(3):148-55. PubMed ID: 6961973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a combination of mitomycin C (NSC-26980), phenylalanine mustard (NSC-14210), and vincristine (NSC-67574) in the treatment of osteogenic sarcoma.
    Jaffe N; Traggis D; Enriquez C
    Cancer Chemother Rep; 1971 Apr; 55(2):189-91. PubMed ID: 5286991
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative antitumor activity of actinomycin analogs in mice bearing Ridgway osteogenic sarcoma or P388 leukemia.
    Rose WC; Trader MW; Laster WR; Schabel FM
    Cancer Treat Rep; 1978 May; 62(5):779-89. PubMed ID: 77730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased cures using fractionated exposures of X irradiation and hyperthermia in the local treatment of the Ridgway osteogenic sarcoma in mice.
    Hahn EW; Alfieri AA; Kim JH
    Radiology; 1974 Oct; 113(1):199-202. PubMed ID: 4529077
    [No Abstract]   [Full Text] [Related]  

  • 5. Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU 1069.
    Siemann DW; Maddison K; Wolf K
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1657-60. PubMed ID: 6548212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of chemotherapy in children with metastatic Ewing's sarcoma and osteogenic sarcoma.
    Sutow WW; Vietti TJ; Fernbach DJ; Lane DM; Donaldson MH; Lonsdale D
    Cancer Chemother Rep; 1971 Feb; 55(1):67-78. PubMed ID: 5287340
    [No Abstract]   [Full Text] [Related]  

  • 7. Variability of tumor response to chemotherapy. I. Contribution of host heterogeneity.
    Simpson-Herren L; Noker PE; Wagoner SD
    Cancer Chemother Pharmacol; 1987; 20(4):297-304. PubMed ID: 3690803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The enhanced response of the Ridgway osteogenic sarcoma to roentgen radiation combined with actinomycin D.
    D'Angio GJ; Maddock CL; Farber S; Brown BL
    Cancer Res; 1965 Aug; 25(7):1002-7. PubMed ID: 5214993
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met-ethoxy HCl against transplantable and spontaneous murine neoplasia.
    Yagi MJ; Bekesi JG
    Cancer Chemother Pharmacol; 1990; 26(3):215-20. PubMed ID: 2357770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actinomycin D: effects on Ridgway osteogenic sarcoma in mice.
    Schwartz HS; Sodergren JE; Sternberg SS; Philips FS
    Cancer Res; 1966 Sep; 26(9):1873-9. PubMed ID: 5224225
    [No Abstract]   [Full Text] [Related]  

  • 11. Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine.
    Merry S; Hamilton TG; Flanigan P; Freshney RI; Kaye SB
    Eur J Cancer; 1991; 27(1):31-4. PubMed ID: 1826436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance patterns of Walker carcinosarcoma 256 and other rodent tumors to cyclophosphamide and L-phenylalanine mustard.
    Schmid FA; Otter GM; Stock CC
    Cancer Res; 1980 Mar; 40(3):830-3. PubMed ID: 7471099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
    Houghton PJ; Cheshire PJ; Myers L; Stewart CF; Synold TW; Houghton JA
    Cancer Chemother Pharmacol; 1992; 31(3):229-39. PubMed ID: 1464161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteogenic sarcoma of the fourth thoracic vertebra. Long-term survival by chemotherapy only.
    Ogihara Y; Sekiguchi K; Tsuruta T
    Cancer; 1984 Jun; 53(12):2615-8. PubMed ID: 6586274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental studies of the antitumor activity of amygdalin MF (NSC-15780) alone and in combination with beta-glucosidase (NSC-128056).
    Laster WR; Schabel FM
    Cancer Chemother Rep; 1975; 59(5):951-65. PubMed ID: 1060511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy in osteogenic sarcoma.
    Tichler TE; Am YB; Brenner HJ
    Prog Clin Biol Res; 1982; 99():49-75. PubMed ID: 6983080
    [No Abstract]   [Full Text] [Related]  

  • 17. Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard.
    Horton JK; Houghton PJ; Houghton JA
    Cancer Res; 1987 Dec; 47(23):6288-93. PubMed ID: 2890432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between the effectiveness of the antitumor action of sarcolysine and the latency period between transplantation and tumor appearance].
    Gavrilova TN; Ladnova GG; Merkulov MF
    Biull Eksp Biol Med; 1978 Feb; 85(2):197-9. PubMed ID: 630096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.
    Bissery MC; Guénard D; Guéritte-Voegelein F; Lavelle F
    Cancer Res; 1991 Sep; 51(18):4845-52. PubMed ID: 1680023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-phenylalanine mustard (NSC-8806) administration in osteogenic sarcoma: an evaluation of dosage schedules.
    Sutow WW; Sullivan MP; Wilbur JR; Vietti TJ; Kaizer H; Nagamoto A
    Cancer Chemother Rep; 1971 Apr; 55(2):151-7. PubMed ID: 5286989
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.